1. Home
  2. FBGL vs ERNA Comparison

FBGL vs ERNA Comparison

Compare FBGL & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FBS Global Limited Ordinary Shares

FBGL

FBS Global Limited Ordinary Shares

N/A

Current Price

$3.65

Market Cap

5.3M

ML Signal

N/A

Logo Eterna Therapeutics Inc.

ERNA

Eterna Therapeutics Inc.

N/A

Current Price

$3.00

Market Cap

5.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FBGL
ERNA
Founded
1996
2018
Country
Singapore
United States
Employees
N/A
N/A
Industry
Miscellaneous manufacturing industries
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3M
5.3M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
FBGL
ERNA
Price
$3.65
$3.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 929.2K
22.2K
Earning Date
04-30-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 31.29
EPS
★ N/A
N/A
Revenue
N/A
★ $582,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.33
$0.13
52 Week High
$4.30
$15.88

Technical Indicators

Market Signals
Indicator
FBGL
ERNA
Relative Strength Index (RSI) 81.09 30.13
Support Level $0.51 $0.23
Resistance Level N/A $4.72
Average True Range (ATR) 0.20 0.34
MACD 0.40 -0.06
Stochastic Oscillator 82.39 9.40

Price Performance

Historical Comparison
FBGL
ERNA

About FBGL FBS Global Limited Ordinary Shares

FBS Global Ltd is a green building contractor and an established interior fit-out specialist in institutional, residential, commercial, and industrial building projects. As a green contractor focused on environmentally sound practices, the company aims to bid tenders for green building projects, use green construction methods and green materials for construction projects, including design, supply, and installation of ceilings, partitions, timber deck, carpet, acoustic wall paneling, built-in furniture, as well as mechanical and electrical services of a building. The company's revenue is derived mainly from the construction contracts and sales of construction materials.

About ERNA Eterna Therapeutics Inc.

Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.

Share on Social Networks: